share_log

Lifeist Wellness Closes Second Tranche With Alumina Partners to Support Mikra’s U.S. Distribution Through GNC Stores

Lifeist Wellness Closes Second Tranche With Alumina Partners to Support Mikra’s U.S. Distribution Through GNC Stores

Lifeist 健康與氧化鋁合作夥伴關閉第二批,以支持米克拉通過 GNC 商店的美國分銷
GlobeNewswire ·  2023/02/01 07:07

Equity capital to facilitate commercial scale production of CELLF

股權資本促進CELLF商業化生產

TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. ("Lifeist" or the "Company") (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: NXTTF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, today announced that it has completed a second tranche under its previously announced draw-down equity facility with Alumina Partners (Ontario) Ltd. ("Alumina"), an affiliate of New York-based private equity firm Alumina Partners, LLC. Gross proceeds to Lifeist were approximately $260,335.

多倫多,2023年2月1日(環球通訊社)--Lifeist Wellness Inc.(“Lifeist”或“公司”)(多倫多證券交易所股票代碼:LFST)(法蘭克福股票代碼:M5B)(OTCMKTS:NXTTF)一家利用科技進步打造能夠改變人類健康的突破性公司的健康科技公司今天宣佈,它已經完成了之前宣佈的與Alumina Partners(Ontario)Ltd.(以下簡稱Alumina)的第二批提現股權安排。Alumina Partners(Ontario)Ltd.是總部位於紐約的私募股權公司Alumina Partners,LLC的附屬公司。Lifeist的總收益約為260,335美元。

"This equity growth capital will help facilitate a successful and timely launch of Mikra's U.S national distribution agreement with health and wellness retail giant GNC over the coming months," commented Meni Morim, Lifeist's Chief Executive Officer. "Alumina is an important partner, having expressed a meaningful vote of confidence in Lifeist and especially our nutraceutical initiatives at Mikra, and providing us with access to capital in a flexible structure that allows us to maintain our debt-free balance sheet."

Lifeist首席執行官Meni Morim表示:“這筆股本增長資本將幫助Mikra在未來幾個月成功和及時地啟動與健康和保健零售巨頭GNC達成的美國全國分銷協議。”Alumina是一個重要的合作伙伴,它對Lifeist,尤其是我們在Mikra的營養計劃投下了有意義的信任票,併為我們提供了以靈活的結構獲得資金的途徑,使我們能夠維持我們的無債務資產負債表。

Added Faraaz Jamal, CEO of Mikra and COO of Lifeist, "We recently commenced commercial scale production of a new and improved version of CELLF. We are privileged to have the support of partners like Alumina to help bring us one step closer to making CELLF available to our customers."

Mikra的首席執行官兼Lifeist的首席運營官Faraaz Jamal補充説:“我們最近開始了CELLF的商業規模生產。我們很榮幸得到像Alumina這樣的合作伙伴的支持,幫助我們向客户提供CELLF又近了一步。”

"We view the GNC CELLF distribution deal as a potential game changer for Lifeist," said Adi Nahmani, Managing Member of Alumina Partners. "We are delighted to see management advancing multiple simultaneous product opportunities, such as their upcoming functional nutrition bar line, and are excited to support the company to continue to execute on all available fronts."

Alumina Partners管理成員阿迪·納赫馬尼表示:“我們認為,GNC CELLF經銷協議可能會改變Lifeist的遊戲規則。”我們很高興看到管理層同時推出多個產品機會,例如他們即將推出的功能性營養棒系列,併為支持該公司繼續在所有可用戰線上執行而感到興奮。“

As previously announced, Lifeist and Alumina Partners entered into an equity financing facility of up to $8 million. Lifeist has the ability to draw down capital on an as-needed basis, minimizing dilution.

正如之前宣佈的那樣,Lifeist和Alumina Partners達成了一項高達800萬美元的股權融資安排。Lifeist有能力根據需要提取資本,將稀釋降至最低。

In connection with the closing of the second tranche under the equity facility, Lifeist issued a total of 4,628,177 units at a price of $0.05625 per unit for gross proceeds of $260,335. Each unit consisted of one common share of Lifeist and one transferable share purchase warrant with each warrant exercisable to acquire one additional common share at a price of $0.09375 for a period of three years. The warrants are subject to an acceleration provision that allows the Company to give notice of an earlier expiry date if the 10-day volume weighted average price of the Company's common shares on the TSXV is equal or greater than $0.1875. The securities are subject to a hold period expiring on June 1, 2023. The proceeds of this second tranche will be used for general corporate purposes, including growth investments for the Mikra nutraceuticals business.

關於股權融資第二批的結束,Lifeist以每單位0.05625美元的價格發行了總計4,628,177個單位,總收益為260,335美元。每個單位包括一股Lifeist普通股和一股可轉讓認股權證,每個認股權證可行使,在三年內以0.09375美元的價格額外獲得一股普通股。該等認股權證須受加速條款規限,如本公司普通股在多倫多證券交易所的10日成交量加權平均價等於或大於0.1875美元,則本公司可發出較早到期日通知。這些證券的持有期將於2023年6月1日到期。這第二部分的收益將用於一般企業用途,包括對Mikra營養食品業務的增長投資。

There are no standby charges or other upfront fees associated with the equity financing facility. Each tranche of units issued under the equity financing facility is subject to the acceptance of the TSX Venture Exchange, and the securities issued will be subject to the customary four-month hold period.

不存在與股權融資安排相關的備用費用或其他預付費用。根據股權融資機制發行的每一批單位均須經多倫多證券交易所創業板接受,而發行的證券將受慣常的四個月持有期所規限。

About Lifeist Wellness Inc.

關於Lifeist Wellness Inc.

Sitting at the forefront of the post-pandemic wellness revolution, Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Portfolio business units include: CannMart, which operates a B2B wholesale distribution business facilitating recreational cannabis sales to Canadian provincial government control boards; CannMart Labs, a BHO extraction facility for the production of high margin cannabis 2.0 products; Australian Vapes, Australia's largest online retailer of vaporizers and accessories; and Mikra, a biosciences and consumer wellness company bringing to market innovative therapies for cellular health.

坐在大流行後健康革命的前沿,Lifeist利用科學和技術的進步,建立了改變人類健康的突破性公司。業務組合包括:CannMart,經營B2B批發分銷業務,促進向加拿大省級政府管制委員會銷售娛樂性大麻;CannMart Labs,BHO提取設施,生產高利潤率大麻2.0產品;Australian Vapes,澳大利亞最大的在線蒸發器及配件零售商;以及Mikra,生物科學和消費者健康公司,將針對細胞健康的創新療法推向市場。

Information on Lifeist and its businesses can be accessed through the links below:

有關Lifeist及其業務的信息可通過以下鏈接訪問:

Contacts

聯繫人

Meni Morim, Lifeist Wellness Inc., CEO
Matt Chesler, CFA, FNK IR, Investor Relations
Ph: 647-362-0390
Email: ir@lifeist.com

Meni Morim,Lifeist Wellness Inc.首席執行官
馬特·切斯勒,CFA,FNK IR,投資者關係
電話:647-362-0390
電子郵件:ir@life ist.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任,也不以任何方式批准或不批准本新聞稿的內容。

Forward Looking Information

前瞻性信息

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements contained herein that are not historical in nature contain forward-looking information. Forward-looking information can be identified by words or phrases such as "may", "expect", "likely", "should", "would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen.

本新聞稿包含適用證券法所指的“前瞻性信息”。本文中包含的所有非歷史性陳述均含有前瞻性信息。前瞻性信息可以通過“可能”、“預期”、“可能”、“應該”、“將”、“計劃”、“預期”、“打算”、“潛在”、“建議”、“估計”、“相信”或這些術語的否定或其他類似的詞語、表達及其語法變體,或某些事件或條件“可能”或“將”發生的陳述來識別。

The forward-looking information contained herein, including, without limitation, statements related to the anticipated launch of the GNC CELLF distribution agreement and any further drawdowns under the Investment Agreement are made as of the date of this press release and is based on assumptions management believed to be reasonable at the time such statements were made, including, without limitation, its ability to successfully launch and fulfill its obligations under the GNC distribution deal and to close a private placement tranche as anticipated, as well as other considerations that are believed to be appropriate in the circumstances. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: issues relating to the production, distribution and sales of CELLF or the inability of Mikra to meet its obligations under the GNC distribution agreement and the inability of the Company to meet the conditions set forth in the Investment Agreement to close any additional tranches thereunder. Additional risk factors can also be found in the Company's current MD&A, which has been filed under the Company's SEDAR profile at . Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

本文包含的前瞻性信息,包括但不限於與GNC CELLF分銷協議的預期推出和投資協議下的任何進一步縮水有關的陳述,是截至本新聞稿發佈之日作出的,基於作出此類陳述時管理層認為合理的假設,包括但不限於其成功推出和履行其在GNC分銷協議下的義務和按預期完成私募部分的能力,以及其他被認為在當時情況下合適的考慮因素。雖然根據管理層目前掌握的信息,我們認為這些假設是合理的,但不能保證這樣的預期將被證明是正確的。就其性質而言,前瞻性信息具有內在的風險和不確定性,這些風險和不確定性可能是一般性的,也可能是具體的,導致預期、預測或結論可能被證明不準確,假設可能不正確,目標、戰略目標和優先事項將無法實現。各種因素,包括已知和未知的風險,其中許多是我們無法控制的,可能會導致實際結果與本新聞稿中的前瞻性信息大不相同。這些因素包括但不限於:與CELLF的生產、分銷和銷售有關的問題,或Mikra無法履行其在GNC分銷協議下的義務,以及公司無法滿足投資協議中規定的條件以完成投資協議項下的任何額外部分。其他風險因素也可以在公司目前的MD&A中發現, 已在公司的SEDAR簡介下提交。告誡讀者不要過度依賴前瞻性信息。除非適用法律要求,否則公司不承擔因新信息、未來事件或其他原因而更新或修改任何前瞻性信息的義務。本新聞稿中包含的前瞻性陳述明確地受到本警示性聲明的限制。

Source: Lifeist Wellness Inc.

來源:Lifeist Wellness Inc.


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論